Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06501612 · ClinicalTrials.gov registry record · NA
Pilot RCT Evaluating Clinical Outcomes of Using Undermyfork Mobile App With Dexcom G7
A NA study of Type 2 Diabetes, sponsored by Scripps Whittier Diabetes Institute.
- Completed
- Registry status
- NA
- Development phase
- 91
- Enrollment target
- 1
- Study location
NCT06501612: Completed NA study of Type 2 Diabetes, sponsored by Scripps Whittier Diabetes Institute.
NCT06501612 is a NA study of Type 2 Diabetes that has completed, run by Scripps Whittier Diabetes Institute. The registered enrollment target is 91 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06501612, a NA study of Type 2 Diabetes, has completed, sponsored by Scripps Whittier Diabetes Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 91 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine if adding using a mobile diabetes-related health application with CGM device yields significant benefits, contributing to our understanding of the potential advantages and informing future diabetes care practices. The rationale for testing CGM with Undermyfork in individuals with T2D stems from the potential benefits of real-time glucose monitoring and personalized dietary tracking in improving glycemic control and reducing diabetes-related complications. Unlike standard care, which often involves periodic fingerstick glucose testing and limited dietary guidance, the proposed intervention offers continuous monitoring and tailored dietary insights, thus potentially improving overall diabetes management outcomes. The proposed intervention, therefore, deviates from standard care by integrating mobile health apps into the routine for CGM use, offering a novel avenue for enhanced glycemic monitoring and management.
Primary Outcome
HbA1c is a person's average blood glucose level over the past three months. This measurement will be collected using lab results provided from healthcare provider. Scores below 7% indicate a healthy HbA1c. Scores above 7% indicate increased risk of diabetes-related complications.
Conditions Studied
Interventions
- OTHER Continuous Glucose Monitor
- OTHER Continuous Glucose Monitor and Undermyfork App
Study Locations (1)
California
- Scripps Whittier Diabetes Institute - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2024-10-09 |
| Est. Completion | 2025-12-05 |
| Phase | NA |
What the finished NCT06501612 record still lists
NCT06501612 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Continuous Glucose Monitor is the first listed.
NCT06501612 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06501612 about?
NCT06501612 is a clinical study titled "Pilot RCT Evaluating Clinical Outcomes of Using Undermyfork Mobile App With Dexcom G7". This study aims to determine if adding using a mobile diabetes-related health application with CGM device yields significant benefits, contributing to our understanding of the potential advantages and informing future diabetes care practices. The rationale for testing CGM with Undermyfork in individ...
What is the current status of trial NCT06501612?
This trial is currently completed. It is a NA study. The enrollment target is 91 participants. The study started on 2024-10-09. Estimated completion is 2025-12-05.
What conditions does trial NCT06501612 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT06501612?
The interventions under investigation include: Continuous Glucose Monitor (OTHER), Continuous Glucose Monitor and Undermyfork App (OTHER).
Who is sponsoring clinical trial NCT06501612?
This trial is sponsored by Scripps Whittier Diabetes Institute, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06501612 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06501612's enrollment target sits among peer trials
91 167th of 327 higher than 161 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI